Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.
The Prostate
View this publicationThe Prostate
View this publicationEuropean journal of nuclear medicine and molecular imaging
View this publicationFrontiers in oncology
View this publicationClinical nuclear medicine
View this publicationEuropean journal of nuclear medicine and molecular imaging
View this publicationDiagnostics (Basel, Switzerland)
View this publicationMolecular imaging
View this publicationPharmaceuticals (Basel, Switzerland)
View this publicationFrontiers in immunology
View this publicationDiagnostics (Basel, Switzerland)
View this publication